KRAS and metastatic malignant neoplasm in the lymph nodes: This means that KRAS mutation analysis should be included in the prognostic stratification of patients resected for PHC, in order to select patients for adjuvant chemotherapy in case of good pathologic results, such as T1–T2 stage or absence of lymph node metastases.